FindTrial
Sign In

TP regimen

DRUG5 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Sichuan Provincial People's Hospital, Shandong Cancer Hospital and Institute, Fudan University, Xiuping Ding

Conditions

Chemotherapy Induced NeutropeniaEsophageal CarcinomaG-CSFHER2-negative Breast CancerImmunotherapyNon-small Cell Lung CancerRadiotherapySolid Tumor Cancer

Phase 2

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer
NCT04499118
Sichuan Provincial People's HospitalHER2-negative Breast Cancer
Start: 2020-08-31End: 2021-08-31Target: 100Updated: 2020-08-05
Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
RecruitingNCT07055841
Xiuping DingSquamous Cell Carcinoma of Head and Neck
Start: 2023-04-01End: 2026-08-01Target: 69Updated: 2025-07-09

Phase 3

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
RecruitingNCT06964568
Fudan UniversityEsophageal Carcinoma, Immunotherapy, Radiotherapy
Start: 2025-02-01End: 2031-02-01Target: 452Updated: 2026-02-10

Unknown Phase

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients
NCT01393080
Tianjin Medical University Cancer Institute and HospitalNon-small Cell Lung Cancer
Start: 2011-03-31End: 2016-12-31Target: 160Updated: 2016-02-17
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
Not yet recruitingNCT06649448
Shandong Cancer Hospital and InstituteChemotherapy Induced Neutropenia, G-CSF, Solid Tumor Cancer
Start: 2024-10-10End: 2026-05-31Target: 200Updated: 2024-10-18